12:00 AM
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SGI-110: Phase II started

Astex began the 2-part, open-label, U.S. Phase II Study SGI-110-03 trial to evaluate subcutaneous SGI-110 on days 1-5 days every 28 days in patients who have failed Nexavar sorafenib therapy. The first part will enroll 15 patients to...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >